股东调查正在研究世代生物公司与XOMA皇家公司的交易是否不公平地有利于内幕人士和损害的股东价值。 A shareholder probe is examining whether Generation Bio’s deal with XOMA Royalty unfairly favored insiders and harmed shareholder value.

Ademi公司正在调查世代生物公司与XOMA皇家公司每股4.2913美元的交易,重点是董事会是否履行信托义务。 The Ademi Firm is investigating Generation Bio’s $4.2913 per share deal with XOMA Royalty Corp., focusing on whether the board upheld fiduciary duties. 股东从现金净额、租赁储蓄和现代特许使用费获得现金和与未来付款挂钩的CVR。 Shareholders get cash and a CVR tied to future payments from net cash, lease savings, and Moderna royalties. 调查检查内幕人员是否有改变管制的优惠条件,以及接受更好报价的处罚是否不公平地限制了股东价值。 The probe examines if change-of-control perks for insiders and a penalty for accepting better offers unfairly limit shareholder value. 该公司正在评估可能违反法律和治理标准的情况,向受影响的投资者提供免费询问。 The firm is assessing potential breaches of law and governance standards, offering free inquiries for affected investors.